search
Back to results

Muscular and Cutaneous Dysfunction in POTS

Primary Purpose

Postural Tachycardia Syndrome

Status
Active
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Patient and Healthy Volunteers training protocol
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postural Tachycardia Syndrome focused on measuring POTS

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria Patients:

  • Informed consent as documented by signature
  • Patients with diagnosed neuropathic POTS
  • Age: ≥18 years and ≤ 60 years

Inclusion Criteria Healthy Volunteers:

  • Informed consent as documented by signature
  • Age: ≥18 years and ≤ 60 years

Exclusion Criteria Patients:

  • Pregnancy and breastfeeding
  • Inability to adhere to the training protocol

Exclusion Criteria Healthy Volunteers:

  • Pregnancy and breastfeeding
  • Intake of vasoactive medication or known, non-treated arterial hypertension
  • Inability to adhere to the training protocol

Sites / Locations

  • Inselspital Bern

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients and Healthy volunteers

Arm Description

Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.

Outcomes

Primary Outcome Measures

Change of early supernormality in%
Change of early super normality as the most important parameter of MVRC measurements during HUT and fatigue in patients with neuropathic POTS compared to healthy subjects.

Secondary Outcome Measures

Change of relative refractory period in msec
During HUT and muscle fatigue
Change of late supernormality period in %
During HUT and muscle fatigue
Change of early supernormality % after Muscle endurance training
Muscle endurance training induced changes of MVRC measurements
Change of relative refractory period in msec after Muscle endurance training
Muscle endurance training induced changes of MVRC measurements
Change of late supernormality in % after Muscle endurance training
Muscle endurance training induced changes of MVRC measurements
Area of palmar sweat production (in cm2)
Qualitative sweat production
Area of plantar sweat production (in cm2)
Qualitative sweat production
Skin wrinkling grade
Skin wrinkling grade
Intramuscular and skin temperature change
Intramuscular and skin temperature changes during HUT and fatigue
Recapillarization time at the lower extremities
Recapillarization time at the lower extremities before and during HUT
Heart rate changes
Heart rate changes during HUT and fatigue
Blood pressure changes
Blood pressure changes during HUT and fatigue
Maximal Tibialis Anterior peak force and endurance time
Maximal Tibialis Anterior peak force and endurance time before and after training
Circumference of the lower legs
Circumference of the lower legs before and after training

Full Information

First Posted
November 12, 2019
Last Updated
July 5, 2022
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT04170725
Brief Title
Muscular and Cutaneous Dysfunction in POTS
Official Title
Muscular and Cutaneous Dysfunction in Postural Tachycardia Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 10, 2020 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
POTS patients seem to experience orthostasis-dependent muscle weakness and pain as well as increased muscle fatigue upon physical activity, which can be improved by regular aerobic exercise. However, reduced sweat production of the extremities with limited control of the body temperature leads to exercise intolerance, so that sticking to a training program becomes a challenge for most patients. Recordings of MVRCs provide a new tool to assess muscle membrane dysfunction, depending on ischemia, surface temperature and training. As muscle dysfunction is assumed to be present in the majority of POTS patients but has not yet been scientifically studied the present study aims at understanding the muscular and cutaneous functioning in POTS using MVRC recordings, dependent both on orthostatic stress and exercise training as well as body temperature regulation. Our main hypothesis is that POTS patients experience functional muscle dysfunction that may be linked to altered muscle perfusion or body temperature regulation. The purpose of this study is to examine muscular and cutaneous dysfunction in POTS in order to i) better understand the underlying pathology for symptoms and to ii) ultimately improve treatment options.
Detailed Description
POTS patients seem to experience orthostasis-dependent muscle weakness and pain as well as increased muscle fatigue upon physical activity, which can be improved by regular aerobic exercise. However, reduced sweat production of the extremities with limited control of the body temperature leads to exercise intolerance, so that sticking to a training program becomes a challenge for most patients. Recordings of MVRCs provide a new tool to assess muscle membrane dysfunction, depending on ischemia, surface temperature and training. As muscle dysfunction is assumed to be present in the majority of POTS patients but has not yet been scientifically studied the present study aims at understanding the muscular and cutaneous functioning in POTS using MVRC recordings, dependent both on orthostatic stress and exercise training as well as body temperature regulation. Our main hypothesis is that POTS patients experience functional muscle dysfunction that may be linked to altered muscle perfusion or body temperature regulation. The purpose of this study is to examine muscular and cutaneous dysfunction in POTS in order to i) better understand the underlying pathology for symptoms and to ii) ultimately improve treatment options. The study includes two examination days with the same procedure for all participants. In between the examination days, participants will undergo an endurance training protocol for 14 days. The first examination day takes place in two parts: Participants will first receive repetitive MVRC recordings of the right tibialis anterior muscle (TA): 1) before, during and after repetitive stimulation of the right TA (intermittent 20Hz for 10 min) in the supine position. Then MVRC recordings will be done from the left TA 2) in the supine position and during the 60° HUT upright position for 10 minutes. The duration of this first part is approximately 60 minutes. The second part consists of a TST of the hands and feet only, including a SWT on the index, middle and ring finger of both hands. This second part also lasts about 60 minutes. On the second examination day, the first part (only 1)) of the first examination day will be repeated. In between the examination days training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 between the examination days. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Tachycardia Syndrome
Keywords
POTS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patients and Healthy volunteers
Arm Type
Experimental
Arm Description
Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
Intervention Type
Other
Intervention Name(s)
Patient and Healthy Volunteers training protocol
Intervention Description
Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
Primary Outcome Measure Information:
Title
Change of early supernormality in%
Description
Change of early super normality as the most important parameter of MVRC measurements during HUT and fatigue in patients with neuropathic POTS compared to healthy subjects.
Time Frame
Day 14
Secondary Outcome Measure Information:
Title
Change of relative refractory period in msec
Description
During HUT and muscle fatigue
Time Frame
Day 14
Title
Change of late supernormality period in %
Description
During HUT and muscle fatigue
Time Frame
Day 14
Title
Change of early supernormality % after Muscle endurance training
Description
Muscle endurance training induced changes of MVRC measurements
Time Frame
Day 14
Title
Change of relative refractory period in msec after Muscle endurance training
Description
Muscle endurance training induced changes of MVRC measurements
Time Frame
Day 14
Title
Change of late supernormality in % after Muscle endurance training
Description
Muscle endurance training induced changes of MVRC measurements
Time Frame
Day 14
Title
Area of palmar sweat production (in cm2)
Description
Qualitative sweat production
Time Frame
Day 1
Title
Area of plantar sweat production (in cm2)
Description
Qualitative sweat production
Time Frame
Day 1
Title
Skin wrinkling grade
Description
Skin wrinkling grade
Time Frame
Day 1
Title
Intramuscular and skin temperature change
Description
Intramuscular and skin temperature changes during HUT and fatigue
Time Frame
Day 14
Title
Recapillarization time at the lower extremities
Description
Recapillarization time at the lower extremities before and during HUT
Time Frame
Day 14
Title
Heart rate changes
Description
Heart rate changes during HUT and fatigue
Time Frame
Day 14
Title
Blood pressure changes
Description
Blood pressure changes during HUT and fatigue
Time Frame
Day 14
Title
Maximal Tibialis Anterior peak force and endurance time
Description
Maximal Tibialis Anterior peak force and endurance time before and after training
Time Frame
Day 14
Title
Circumference of the lower legs
Description
Circumference of the lower legs before and after training
Time Frame
Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Patients: Informed consent as documented by signature Patients with diagnosed neuropathic POTS Age: ≥18 years and ≤ 60 years Inclusion Criteria Healthy Volunteers: Informed consent as documented by signature Age: ≥18 years and ≤ 60 years Exclusion Criteria Patients: Pregnancy and breastfeeding Inability to adhere to the training protocol Exclusion Criteria Healthy Volunteers: Pregnancy and breastfeeding Intake of vasoactive medication or known, non-treated arterial hypertension Inability to adhere to the training protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Werner Z'Graggen, MD
Organizational Affiliation
Inselspital Bern, Department of Neurosurgery & Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Inselspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25009504
Citation
Anderson JW, Lambert EA, Sari CI, Dawood T, Esler MD, Vaddadi G, Lambert GW. Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS). Front Physiol. 2014 Jun 25;5:230. doi: 10.3389/fphys.2014.00230. eCollection 2014.
Results Reference
background
PubMed Identifier
22692998
Citation
Boerio D, Z'Graggen WJ, Tan SV, Guetg A, Ackermann K, Bostock H. Muscle velocity recovery cycles: effects of repetitive stimulation on two muscles. Muscle Nerve. 2012 Jul;46(1):102-11. doi: 10.1002/mus.23267.
Results Reference
background
PubMed Identifier
22806376
Citation
Bostock H, Baumann C, Humm AM, Z'graggen WJ. Temperature dependency of human muscle velocity recovery cycles. Muscle Nerve. 2012 Aug;46(2):264-6. doi: 10.1002/mus.23429.
Results Reference
background
PubMed Identifier
12963801
Citation
Bostock H, Campero M, Serra J, Ochoa J. Velocity recovery cycles of C fibres innervating human skin. J Physiol. 2003 Dec 1;553(Pt 2):649-63. doi: 10.1113/jphysiol.2003.046342. Epub 2003 Sep 8.
Results Reference
background
PubMed Identifier
25829642
Citation
Deb A, Morgenshtern K, Culbertson CJ, Wang LB, Hohler AD. A survey-based analysis of symptoms in patients with postural orthostatic tachycardia syndrome. Proc (Bayl Univ Med Cent). 2015 Apr;28(2):157-9. doi: 10.1080/08998280.2015.11929217.
Results Reference
background
PubMed Identifier
21431947
Citation
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. doi: 10.1007/s10286-011-0119-5. No abstract available.
Results Reference
background
PubMed Identifier
21393070
Citation
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz IJ, Schondorf R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011 Apr 26;161(1-2):46-8. doi: 10.1016/j.autneu.2011.02.004. Epub 2011 Mar 9. No abstract available.
Results Reference
background
PubMed Identifier
25487551
Citation
Fu Q, Levine BD. Exercise in the postural orthostatic tachycardia syndrome. Auton Neurosci. 2015 Mar;188:86-9. doi: 10.1016/j.autneu.2014.11.008. Epub 2014 Nov 21.
Results Reference
background
PubMed Identifier
30001836
Citation
Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018 Dec;215:20-27. doi: 10.1016/j.autneu.2018.07.001. Epub 2018 Jul 4.
Results Reference
background
PubMed Identifier
18506020
Citation
Grubb BP. Postural tachycardia syndrome. Circulation. 2008 May 27;117(21):2814-7. doi: 10.1161/CIRCULATIONAHA.107.761643. No abstract available.
Results Reference
background
PubMed Identifier
21653205
Citation
Humm AM, Bostock H, Troller R, Z'Graggen WJ. Muscle ischaemia in patients with orthostatic hypotension assessed by velocity recovery cycles. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1394-8. doi: 10.1136/jnnp-2011-300444. Epub 2011 Jun 7.
Results Reference
background
PubMed Identifier
11018167
Citation
Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, Biaggioni I, Ertl A, Black B, Robertson D. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000 Oct 5;343(14):1008-14. doi: 10.1056/NEJM200010053431404.
Results Reference
background
PubMed Identifier
30879357
Citation
Jacob G, Diedrich L, Sato K, Brychta RJ, Raj SR, Robertson D, Biaggioni I, Diedrich A. Vagal and Sympathetic Function in Neuropathic Postural Tachycardia Syndrome. Hypertension. 2019 May;73(5):1087-1096. doi: 10.1161/HYPERTENSIONAHA.118.11803.
Results Reference
background
PubMed Identifier
25120493
Citation
Lambert E, Lambert GW. Sympathetic dysfunction in vasovagal syncope and the postural orthostatic tachycardia syndrome. Front Physiol. 2014 Jul 28;5:280. doi: 10.3389/fphys.2014.00280. eCollection 2014.
Results Reference
background
PubMed Identifier
17626834
Citation
Masuki S, Eisenach JH, Schrage WG, Johnson CP, Dietz NM, Wilkins BW, Sandroni P, Low PA, Joyner MJ. Reduced stroke volume during exercise in postural tachycardia syndrome. J Appl Physiol (1985). 2007 Oct;103(4):1128-35. doi: 10.1152/japplphysiol.00175.2007. Epub 2007 Jul 12.
Results Reference
background
PubMed Identifier
8423877
Citation
Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993 Jan;43(1):132-7. doi: 10.1212/wnl.43.1_part_1.132.
Results Reference
background
PubMed Identifier
25980576
Citation
Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015 Jun;12(6):e41-63. doi: 10.1016/j.hrthm.2015.03.029. Epub 2015 May 14. No abstract available.
Results Reference
background
PubMed Identifier
22641777
Citation
Shibata S, Fu Q, Bivens TB, Hastings JL, Wang W, Levine BD. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol. 2012 Aug 1;590(15):3495-505. doi: 10.1113/jphysiol.2012.233858. Epub 2012 May 28.
Results Reference
background
PubMed Identifier
22806368
Citation
Tan SV, Z'graggen WJ, Boerio D, Rayan DL, Howard R, Hanna MG, Bostock H. Membrane dysfunction in Andersen-Tawil syndrome assessed by velocity recovery cycles. Muscle Nerve. 2012 Aug;46(2):193-203. doi: 10.1002/mus.23293.
Results Reference
background
PubMed Identifier
24037712
Citation
Tan SV, Z'Graggen WJ, Boerio D, Rayan DR, Norwood F, Ruddy D, Howard R, Hanna MG, Bostock H. Chloride channels in myotonia congenita assessed by velocity recovery cycles. Muscle Nerve. 2014 Jun;49(6):845-57. doi: 10.1002/mus.24069. Epub 2014 May 2.
Results Reference
background
PubMed Identifier
19375384
Citation
Wilder-Smith EP, Guo Y, Chow A. Stimulated skin wrinkling for predicting intraepidermal nerve fibre density. Clin Neurophysiol. 2009 May;120(5):953-8. doi: 10.1016/j.clinph.2009.03.011. Epub 2009 Apr 16.
Results Reference
background
PubMed Identifier
20181515
Citation
Z'Graggen WJ, Aregger F, Farese S, Humm AM, Baumann C, Uehlinger DE, Bostock H. Velocity recovery cycles of human muscle action potentials in chronic renal failure. Clin Neurophysiol. 2010 Jun;121(6):874-81. doi: 10.1016/j.clinph.2010.01.024. Epub 2010 Feb 23.
Results Reference
background
PubMed Identifier
19229874
Citation
Z'graggen WJ, Bostock H. Velocity recovery cycles of human muscle action potentials and their sensitivity to ischemia. Muscle Nerve. 2009 May;39(5):616-26. doi: 10.1002/mus.21192.
Results Reference
background
PubMed Identifier
21044861
Citation
Z'Graggen WJ, Brander L, Tuchscherer D, Scheidegger O, Takala J, Bostock H. Muscle membrane dysfunction in critical illness myopathy assessed by velocity recovery cycles. Clin Neurophysiol. 2011 Apr;122(4):834-41. doi: 10.1016/j.clinph.2010.09.024. Epub 2010 Nov 1.
Results Reference
background
PubMed Identifier
27104654
Citation
Z'Graggen WJ, Trautmann JP, Bostock H. Force training induces changes in human muscle membrane properties. Muscle Nerve. 2016 Jun;54(1):144-6. doi: 10.1002/mus.25149.
Results Reference
background
PubMed Identifier
21555240
Citation
Z'graggen WJ, Troller R, Ackermann KA, Humm AM, Bostock H. Velocity recovery cycles of human muscle action potentials: repeatability and variability. Clin Neurophysiol. 2011 Nov;122(11):2294-9. doi: 10.1016/j.clinph.2011.04.010. Epub 2011 May 8.
Results Reference
background
PubMed Identifier
30809183
Citation
Ziemssen T, Siepmann T. The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review. Front Neurol. 2019 Feb 12;10:53. doi: 10.3389/fneur.2019.00053. eCollection 2019.
Results Reference
background

Learn more about this trial

Muscular and Cutaneous Dysfunction in POTS

We'll reach out to this number within 24 hrs